Pakistan Pharmaceutical Manufacturers Association (PPMA) Chairman Mian Khalid Misbah-ur-Rehman has highlighted the key challenges facing Pakistan’s pharmaceutical sector, particularly drug shortages and pricing policies.
Chairman Khalid Misbah-ur-Rehman, during a show on Aaj News, emphasized the need for immediate action to solve the problem of shortage of medicines in the country, saying that the government’s deregulation of unnecessary medicines and reduction in prices would help. The problems may gradually be solved, but the problem of essential medicines will remain.
He pointed out that the government has capped annual price increases of essential medicines at 7 percent, which is low given the significant inflation and currency devaluation in recent years.
Misbah-ur-Rehman emphasized the need for a more flexible pricing policy that can be adapted to economic realities.
He called for a review of Pakistan’s pricing policies to ensure that they are fair and reflect the economic challenges facing the country.
He further said that there are 494 drugs in Pakistan’s list of essential drugs which is the largest in the region. The list includes 384 medicines from India, 120 from Bangladesh and only 60 from Sri Lanka.
From which health sector did the pharma sector become silver?
Talking regarding regulatory issues, Misbah-ur-Rehman expressed concern over the outdated Drugs Act of 1976, which has not been revised in line with modern standards and practices in the pharmaceutical industry.
He highlighted the need for the Drug Regulatory Authority of Pakistan (DRAP) to have adequate staff and equipment to effectively deal with regulatory challenges.
Misbah-ur-Rehman emphasized that ‘if the law has given autonomy to DRAP, then people also need to exercise this autonomy’.
He also pointed out the challenges faced by the regulatory authority due to lack of continuity in director appointments.
Misbah-ur-Rehman also criticized the current approach to minor manufacturing defects, saying that while international standards focus on warning and investigation, Pakistan’s laws often lead to criminal prosecution, and not It was seen what was intended.
The decision to deregulate the maximum price of medicines is expected to improve
He stressed the need for a more sophisticated approach to quality control issues to prevent pharmaceutical companies from being penalized unnecessarily.
Misbah-ur-Rehman expressed hope that the recent deregulation of non-essential drugs would improve the availability and prices of some non-essential drugs by increasing competition.
However, he stressed that more comprehensive reforms are needed to address the underlying issues facing Pakistan’s pharmaceutical sector.
He urged the government to work with industry stakeholders to develop policies that promote growth and sustainability, and ensure patients have access to affordable and high-quality medicines.
Indian pharmaceutical companies are infamous worldwide for substandard drugs
Misbah-ur-Rehman emphasized the importance of a collaborative approach to reform involving all relevant parties to achieve meaningful change.
Thus PPMA Chairman Misbah-ur-Rehman’s call for urgent reforms highlights the need for decisive action to improve the efficiency of the sector and address the issues of drug shortages and pricing policies.
#Supply #affordable #quality #medicines #Govt #develop #joint #policy #pharma #industry #Chairman #PPMA #Pakistan
2024-05-04 14:31:24